MDACC Study No:2009-0296 ( NCT No: NCT00867113)
Title:A Phase II, non-randomized, open-label multicenter study
of 5 year adjuvant imatinib mesylate (GleevecŪ) in patients
at significant risk for recurrence following complete
resection of primary gastrointestinal stromal tumor (GIST)
Principal Investigator:Dejka M. Araujo
Treatment Agent:STI571
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if taking imatinib
mesylate (GleevecŪ) for 5 years can help to prevent the disease from possibly
coming back in patients who have had surgery to remove a GIST.
Hide details for General InformationGeneral Information

Disease Group:GIST
Phase of Study:Phase II
Treatment Agents:STI571
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Novartis
Return Visit:Screening, Day1, Day 15, Day 29, then every 6 mos for next 2 years. years.
Home Care:Patient will self administer the STI-571 at home.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Dejka M. Araujo
Dept:Sarcoma Medical Oncology
For Clinical Trial Enrollment:713-792-3626
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults